Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: Findings from the Heart and Soul Study

https://escholarship.org/uc/item/7qj089wn

JOURNAL OF PSYCHIATRIC RESEARCH, 47(9)

0022-3956

Prather, AA
Epel, ES
Cohen, BE
et al.

2013-09-01

10.1016/j.jpsychires.2013.05.004

Peer reviewed
Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: Findings from the Heart and Soul Study

Aric A. Prather, Elissa S. Epel, Beth E. Cohen, Thomas C. Neylan, Mary A. Whooley

Abstract

Systemic inflammation is proposed as a putative mechanism underlying the link between poor sleep and cardiovascular disease. The aim of present study was to investigate the cross-sectional and prospective associations of self-reported sleep quality with biomarkers of inflammation and coagulation implicated in coronary heart disease (CHD) and to explore whether these associations differed between men and women. To this end, measures of sleep quality and markers of inflammation, including circulating levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (CRP), and fibrinogen were assessed at baseline in 980 participants with established CHD and 626 at 5-year follow-up. In the sample as a whole, subjective sleep quality was unrelated to inflammatory markers in cross-sectional and prospective analyses. However, in gender stratified analyses, adjusting for age, ethnicity, education, body mass index, and regular snoring, poorer subjective sleep quality at baseline was prospectively associated with 5-year increases in circulating IL-6 that withstood covariate adjustment. Further analyses, adjusting for age, ethnicity, education, body mass index, and regular snoring, showed significant 5-year increases in circulating IL-6 that withstood covariate adjustment. Further research is necessary to elucidate the pathways that underlie gender-specific associations between subjective sleep quality and markers of inflammation and coagulation as this may help clarify gender disparities in CHD.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Growing evidence supports disturbed sleep as a behavioral risk factor for incidence and progression of a number of chronic medical conditions, including coronary heart disease (CHD) (Ayas et al., 2003a, 2003b; Gangwisch et al., 2006, 2010, 2007; Gottlieb et al., 2006; Hall et al., 2008; Mallon et al., 2002). These associations are not limited to objectively defined measures of sleep but also include an individual’s subjective report of sleep quality. For instance, women with established coronary heart disease who reported poor sleep quality were 2.6 times more likely to experience a cardiac event than women reporting good sleep quality (Leineweber et al., 2003). The biological mechanisms that underlie associations between disrupted sleep and cardiovascular disease remain to be elucidated; however, recent research implicates sleep-related changes in markers of inflammation as one plausible pathway (Miller and Cappuccio, 2007; Motivala, 2011; Mullington et al., 2009; Simpson and Dinges, 2007).

Circulating levels of proinflammatory cytokines (e.g. interleukin (IL)-6), acute phase proteins (C-reactive protein), and pro-coagulation factors (e.g. fibrinogen) are strongly implicated in the pathophysiology of CHD and are elevated in CHD patients (Palmieri et al., 2003; Ridker et al., 2000a; Ridker et al., 2000b; Sarwar et al., 2009; Stec et al., 2000). Elevated systemic levels of inflammation contribute to CHD by accelerating the development and progression of atherosclerotic plaques (Libby, 2002; Ross, 1999) and
activating pro-coagulation pathways (Danesh et al., 1998; Kannel et al., 1987). Sleep has emerged as an important health behavior associated with inflammatory activity in humans (Miller, 2011). Indeed, epidemiologic and laboratory studies demonstrate that poor sleep, characterized by short sleep duration (e.g., <6 h per night), poor continuity, and poor subjective sleep quality, is associated with elevations in markers of inflammation in most (Hong et al., 2005; Matthews et al., 2010; Meier-Ewert et al., 2004; Miller et al., 2009; Okun et al., 2009; Suarez, 2008; Vgontzas et al., 2004); but not all studies (Patel et al., 2009; Taheri et al., 2007). Recent evidence suggests the association between disrupted sleep and markers of inflammation are stronger in women than men (Irwin et al., 2010; Miller et al., 2009; Suarez, 2008). For instance, women reporting poor sleep quality and a greater frequency of disturbed sleep symptoms displayed elevated levels of IL-6 and CRP while no such association was observed in men (Suarez, 2008). Further, in a sub-analysis of the Whitehall II Study, shorter sleep duration was related to higher levels of circulating IL-6 and CRP in women but not men (Miller et al., 2009). While this evidence is limited to cross-sectional investigations, these findings are consistent with a prior report that found disturbed sleep to be a significant risk factor for cardiovascular disease in older women but not men (Newman et al., 2000).

The present study aims to extend prior cross-sectional literature in a sample of men and women with established coronary heart disease. To this end, we examined the associations of self-reported sleep quality with baseline, 5-year follow-up, and 5-year changes in circulating IL-6, CRP, and fibrinogen in a sample of men and women who participated in the Heart and Soul Study. It was hypothesized that poorer subjective sleep quality would be associated with higher levels of these biomarkers in cross-sectional analyses as well as greater 5-year increases when assessed prospectively. Furthermore, we hypothesized, based on existing evidence, that associations of subjective sleep quality with biomarkers would be stronger in women as compared to men.

2. Methods

2.1. Participants

The Heart and Soul Study is a prospective cohort study of psychosocial factors and health outcomes in patients with established CHD. Method have been described previously (Whooley et al., 2007). Briefly, participants were recruited from two separate Veterans Affairs Medical Centers (San Francisco and Palo Alto), one university medical center (University of California, San Francisco), and nine public health clinics in the Community Health Network of San Francisco. Participants were eligible to participate if they had a history of the following: myocardial infarction (MI), angiographic evidence ≥50% stenosis in one of more coronary vessels, prior evidence of exercise induced ischemia by treadmill or nuclear testing, or coronary revascularization. Patients were ineligible for the study if they had acute coronary syndrome within the past 6 months, could not walk one block, or were planning to move out of the local area within 3 years.

Between September 2000 and December 2002, a total of 1024 participants enrolled and completed a daylong study protocol at the San Francisco Veterans Affairs Medical Center. Between September 2005 and December 2007, 667 participants (80% of the 829 survivors) completed a 5-year follow-up examination. Circulating levels of IL-6, CRP, and fibrinogen were available on 985 participants at baseline and 661 at the 5-year follow-up. The appropriate institutional review boards approved the Heart and Soul Study protocol, and all participants provided written, informed consent.

2.2. Sleep measures

Subjective sleep quality was measured using a single item from the Pittsburgh Sleep Quality Index (PSQI), a self-rated questionnaire that assesses sleep quality and disturbances (Buysse et al., 1989). Participants were asked at baseline and 5 years later: “During the past month, how would you rate your overall sleep quality?” and indicated: “very good”, “fairly good”, “good”, “fairly bad”, “very bad”, scored from 0 to 4, with higher scores indicating poorer sleep quality. This single-item measure is what comprises the sleep quality subscale for the full PSQI scale. As compared to the other PSQI subscales, the sleep quality subscale shows the highest correlation with the PSQI global sleep quality score (r’s = 0.76–0.83) across several different populations (Bush et al., 2012; Carpenter and Andrýkowski, 1998). PSQI subjective sleep quality was treated as a continuous variable in all analyses. Secondary sleep variables were also administered, modified from the Cardiovascular Health Study, which were self-report items to assess difficulty initiating and maintaining sleep, including difficulty falling asleep, frequent awakenings, and waking too early (Newman et al., 1997). Specifically, participants were asked to answer “yes” or “no” to the following questions: “Do you usually have trouble falling asleep?”, “Do you usually wake up several times at night?”, and “Do you usually wake up far too early?” These secondary sleep measures were obtained at baseline only.

2.3. Biomarkers

Participants were asked to fast for 12 h (except for medications, which they were able to take with water), not take aspirin for 1 week, and not to smoke for 5 h before their study appointment. Venous blood samples were obtained at baseline and 5 year follow-up. Plasma and serum samples were stored at −70 °C for measurement of CRP, IL-6, and fibrinogen.

CRP was quantified using the Roche Integra high-sensitivity assay or the Beckman Extended Range assay at baseline and using the Roche Integra high-sensitivity assay at 5-year follow-up. Results from the two assays using baseline samples were highly correlated (r = 0.99 in 185 participants). IL-6 was determined using high-sensitivity enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, Minnesota). The inter-assay coefficient of variation is 6.5%–9.6%, and the intra-assay coefficient of variation is 6.9%–7.8%. The reportable range for IL-6 is 0.428–8.87 pg/ml.

Fibrinogen levels were determined by the Clauss assay. Dilutions of the plasma standard (of known concentrations) were clotted with a high concentration of thrombin, with the resultant clotting time being proportional to the fibrinogen concentration. The clotting time of the participant’s plasma was used to read the fibrinogen concentration from the standard curve. The standard assay range is from 60 to 10,000 mg/dL and the interassay coefficient of variation are both <3%.

2.4. Other participant characteristics

Sociodemographic characteristics, including age, gender, ethnicity (Caucasian vs. non-Caucasian), and education (high school graduate vs. non-high school graduate) were determined by self-report questionnaire as were health behaviors including alcohol consumption, and smoking status. Similarly, participants completed a questionnaire on medical comorbidities, including history of hypertension, myocardial infarction, congestive heart failure, type 2 diabetes, and stroke. Because sleep disordered breathing is a strong predictor of CHD (Cottlieb et al., 2010; Shahar et al., 2001), body mass index (BMI) was calculated based on recorded heights and weights (weight in kilograms divided by the
square of height in meters) and participants were asked “Have you ever snored?” and, if yes, “How often do you snore now?” (none, a little, some, much, or all of the time). History of regular snoring was defined as “much” or “all of the time”.

Physical activity was determined with the multiple choice question, “which of the following statements best describes how physically active you have been during the past month, that is, done activities such as 15–20 min of brisk walking, swimming, general conditioning, or recreational sports?” Participants who answered fairly, very, or extremely active (vs. not at all or a little active) were considered physically active (Whooley et al., 2008).

Cardiac function was assessed with systolic blood pressure and left ventricular ejection fraction (LVEF) from a resting echocardiogram. Participants were instructed to bring all of their medication bottles to the study appointment, and trained research assistants recorded all current medications. History of medications included use of beta-blockers, ACE inhibitors, statins, antidepressants, benzodiazepines, and hormone replacement therapy/oral contraceptives. Finally, depressive symptoms over the past week were assessed using the Center for Epidemiologic Studies of Depression Scale (CES-D) (Radloff, 1977).

### 2.5. Data analysis

The goal of this study was to examine the cross-sectional and prospective associations of PSQI subjective sleep quality with baseline, 5-year, and 5-year changes in levels of IL-6, CRP, and fibrinogen in men and women with stable CHD. Linear regression models were computed adjusting for sociodemographic characteristics (age, gender, ethnicity, education, body mass index), and regular snoring in the first step, followed by PSQI subjective sleep quality entered as a continuous variable in the second step of each model. If a regression model was statistically significant, additional covariates were added step-wise in groups as follows: lifestyle/psychosocial variables (cigarette smoking status, physical activity, alcohol consumption, and depressive symptoms); history of medical comorbidities (hypertension, myocardial infarction, congestive heart failure, type 2 diabetes, and stroke); history of medication use (beta-blockers, statins, ACE inhibitors, hormone replacement therapy/oral contraceptive, antidepressant, and benzodiazepine use); and cardiac function (resting systolic blood pressure, and resting left ventricular ejection fraction), with PSQI subjective sleep quality entered as the final variable in the model. In instances where covariates were measured at baseline and 5-year time points, we included covariates consistent with the time frame of the dependent variable. Analyses predicting changes in levels of IL-6, CRP, and fibrinogen over the 5-year span of the study were computed by treating the 5-year biomarker as the dependent variable and statistically adjusting for baseline levels of the biomarker of interest.

To evaluate the moderating effects of gender, an interaction term (gender by PSQI subjective sleep quality) was computed and entered into the final step of the regression models. If the interaction term emerged as a significant predictor, gender-stratified regression analyses, adjusting sociodemographic characteristics, and regular snoring were carried out. If statistically significant, additional covariates were included in a stepwise manner as described above. To evaluate the role of sleep disturbances (difficulty initiating sleep, frequent awakening, and waking too early) on 5-year changes in IL-6, CRP, and fibrinogen, analyses were conducted on the sample as a whole and stratified by gender if supported by a significant interaction term. CRP and IL-6 values underwent a natural log transformation because they were not normally distributed. Fibrinogen values were normally distributed. Analyses were restricted to participants with complete data on PSQI subjective sleep quality and markers of inflammation at baseline (n = 980) and 5-year follow-up (n = 626).

### 3. Results

#### 3.1. Sample characteristics

Sample characteristics for participants who had complete sleep quality and inflammation data at baseline (n = 980) and at baseline and 5-year follow up (n = 626) are provided in Table 1. Compared to the group of participants with baseline and follow-up data, those without follow-up data were older (t(976) = 2.86, p < 0.005), regular snorers (X²(1) = 5.23, p < 0.02), more depressed (t(977) = 3.32, p < 0.001), smokers (X²(1) = 10.54, p < 0.005), less physically active (X²(1) = 6.68, p < 0.01), had a history of congestive heart failure (X²(1) = 8.21, p < 0.005), diabetes (X²(1) = 7.37, p < 0.01), stroke (X²(1) = 4.46, p < 0.04), were taking statins.
(X^2(1) = 18.00, p < 0.001) and antidepressants (X^2(1) = 7.16, p < 0.008), had a lower left ventricular ejection fraction (t(976) = 2.75, p < 0.007) and higher levels of inflammation (IL-6: t(976) = 5.56, p < 0.001; CRP: t(976) = 4.70, p < 0.001) and coagulation (fibrinogen: t(976) = 3.60, p < 0.001). Those without follow-up data were also more likely to report difficulties falling asleep (X^2(1) = 12.91, p < 0.001) and awaking too early (X^2(1) = 4.35, p = 0.04); however, these groups did not differ in levels of self-reported sleep quality (t(976) = 0.95, p = 0.34).

At baseline, participants reporting poorer PSQI subjective sleep quality were younger, more likely to be a regular snorer, to smoke, be inactive, have hypertension, take antidepressants, take benzodiazepines, and reported more depressive symptoms (p's < 0.05). At follow-up, poorer PSQI subjective sleep quality was associated with being younger, being inactive, having a higher BMI, being less likely to take ACE inhibitors, being more likely to take antidepressants and benzodiazepines, and reporting more depressive symptoms (p's < 0.05). As expected, baseline and 5-year levels of IL-6, CRP, and fibrinogen were inter-correlated (r's = 0.26–0.59, p's < 0.001).

### 3.2. Sleep quality and markers of inflammation and coagulation

Table 2 displays the cross-sectional associations between baseline and 5-year PSQI subjective sleep quality with levels of IL-6, CRP, and fibrinogen. At baseline and follow-up, PSQI subjective sleep quality was unrelated to circulating levels of these biomarkers with the exception of baseline levels of fibrinogen. In this regard, poorer PSQI subjective sleep quality was associated with lower levels of fibrinogen, independent of sociodemographic factors and regular snoring; however, when the next block of covariates was included in the model (i.e., lifestyle/psychosocial factors), this relationship fell below statistical significance (b = -4.72, SE = 2.88, p = 0.10). Next, we tested the prospective associations between baseline PSQI subjective sleep quality and 5-year changes in levels of IL-6, CRP, and fibrinogen. Linear regression models revealed no statistically significant associations between PSQI subjective sleep quality and 5-year changes in these biomarkers.

### 3.3. Gender differences in associations of sleep quality with biomarkers

Baseline characteristics for participants stratified by gender are presented in Table 3. At baseline, women were younger, more ethnically diverse, and less educated compared to men. They also reported higher depressive symptoms, were more likely to be taking antidepressants, and less likely than men to have a history of taking beta-blockers, statins, and ACE/ARB inhibitors. Finally, compared to men, women had higher systolic blood pressure, resting left ventricular ejection fraction and circulating levels of CRP. There were no gender differences in baseline levels of IL-6, fibrinogen, or any on of the sleep measures. Furthermore, 5-year changes in circulating levels of IL-6, CRP, and fibrinogen were similar in men and women (p's ranged from 0.14 to 0.90).

Based on the prior literature, we investigated whether gender moderates associations of PSQI subjective sleep quality with levels of inflammation and coagulation in cross-sectional and prospective analyses. Here, adjusting for sociodemographic characteristics and regular snoring, a significant interaction term (gender by PSQI subjective sleep quality) emerged as an independent predictor of baseline IL-6 (interaction: b = -0.12, SE = 0.05, p = 0.02) and 5-year changes in all three biomarkers (interactions: IL-6: b = -0.18, SE = 0.06, p = 0.001; CRP: b = -0.26, SE = 0.10, p = 0.01; fibrinogen: b = -0.19, SE = 0.07, p = 0.01).

Analyses stratified by gender were carried out for models supporting a significant gender by PSQI subjective sleep quality interaction. As displayed in Table 4, poorer PSQI subjective sleep quality

---

**Table 2**

Baseline characteristics stratified by gender. Values displayed as means (standard deviation) and percentages.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Men (n = 514)</th>
<th>Women (n = 112)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sociodemographic variables</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>66.3 (10.1)</td>
<td>64.2 (10.1)*</td>
</tr>
<tr>
<td>Ethnicity (% Caucasian)</td>
<td>63.6%</td>
<td>46.4%</td>
</tr>
<tr>
<td>Education (% high graduate or higher)</td>
<td>89.5%</td>
<td>81.3%</td>
</tr>
<tr>
<td><strong>Body mass index (kg/m^2)</strong></td>
<td>28.4 (4.9)</td>
<td>29.3 (6.1)</td>
</tr>
<tr>
<td><strong>History of regular snoring (% yes)</strong></td>
<td>20.0%</td>
<td>24.1%</td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>68.3%</td>
<td>70.5%</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>54.0%</td>
<td>46.8%</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>15.6%</td>
<td>12.6%</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>23.0%</td>
<td>25.9%</td>
</tr>
<tr>
<td>Stroke</td>
<td>12.5%</td>
<td>11.6%</td>
</tr>
<tr>
<td><strong>Medication history</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta blockers</td>
<td>59.3%</td>
<td>48.2%</td>
</tr>
<tr>
<td>Statins</td>
<td>72.2%</td>
<td>55.4%</td>
</tr>
<tr>
<td>ACE/ARBs (angiotensin)</td>
<td>52.3%</td>
<td>42.0%</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>13.8%</td>
<td>25.9%</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>7.6%</td>
<td>9.8%</td>
</tr>
<tr>
<td>OC/HT (women)</td>
<td>0.0%</td>
<td>3.6%</td>
</tr>
<tr>
<td><strong>Cardiac function</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>131.6 (20.3)</td>
<td>137.5 (20.5)*</td>
</tr>
<tr>
<td>Resting LVEF</td>
<td>0.62 (0.09)</td>
<td>0.65 (0.07)*</td>
</tr>
<tr>
<td><strong>Lifestyle/psychosocial variables</strong></td>
<td>37.3%</td>
<td>14.5%</td>
</tr>
<tr>
<td>Regular alcohol use</td>
<td>33.7%</td>
<td>14.5%</td>
</tr>
<tr>
<td>Current smoking</td>
<td>17.3%</td>
<td>14.3%</td>
</tr>
<tr>
<td>Physically active</td>
<td>37.4%</td>
<td>29.7%</td>
</tr>
<tr>
<td>CES-D depression score</td>
<td>6.8 (5.4)</td>
<td>8.4 (5.7)*</td>
</tr>
<tr>
<td><strong>Sleep measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSQI subjective sleep quality</td>
<td>1.8 (1.1)</td>
<td>1.8 (1.1)</td>
</tr>
<tr>
<td>Difficult falling asleep</td>
<td>30.9%</td>
<td>36.0%</td>
</tr>
<tr>
<td>Frequent awakenings</td>
<td>78.2%</td>
<td>81.3%</td>
</tr>
<tr>
<td>Waking too early</td>
<td>40.7%</td>
<td>49.5%</td>
</tr>
<tr>
<td><strong>Biomarkers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin-6 (pg/mL)</td>
<td>2.43 (1.54–3.67)</td>
<td>2.04 (1.36–3.56)</td>
</tr>
<tr>
<td>Median (IQR)^d</td>
<td>2.15 (0.68–3.92)</td>
<td>2.81 (1.15–6.37)*</td>
</tr>
<tr>
<td>C-reactive protein (mg/L), median (IQR)^d</td>
<td>385.4 (84.7)</td>
<td>378.6 (78.6)</td>
</tr>
</tbody>
</table>

*p < 0.05.

Angiotensin converting enzyme/angiotensin II receptor blocker (ACE/ARB); Oral contraceptive/hormone replacement therapy (OR/HT); Blood pressure (BP); Left ventricular Ejection Fraction (LVEF); Center for Epidemiologic Studies of Depression Scale (CES-D); Pittsburgh Sleep Quality Index (PSQI).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>5-Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circulating IL-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSQI subjective sleep quality</td>
<td>-0.01</td>
<td>0.00</td>
</tr>
<tr>
<td>Circulating CRP</td>
<td>-0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>Circulating fibrinogen</td>
<td>-6.70</td>
<td>-0.33</td>
</tr>
</tbody>
</table>

---

*p = 0.05.

Angiotensin converting enzyme/angiotensin II receptor blocker (ACE/ARB); Oral contraceptive/hormone replacement therapy (OR/HT); Blood pressure (BP); Left ventricular Ejection Fraction (LVEF); Center for Epidemiologic Studies of Depression Scale (CES-D); Pittsburgh Sleep Quality Index (PSQI).

Table 2: Cross-sectional results of linear regressions examining baseline and 5-year PSQI subjective sleep quality associations with baseline and 5-year levels of IL-6, CRP, and fibrinogen. Models adjusted for age, gender, ethnicity, education, BMI, and regular snoring.
at baseline was significantly associated with 5-year increases in IL-6, CRP, and fibrinogen in women but not men. These associations remained statistically significant after adjustment for sociodemographic characteristics, lifestyle/psychosocial variables, medical comorbidities, medication use, and cardiac function (Table 5).

A significant gender by PSQI subjective sleep quality interaction was also observed in predicting baseline levels of IL-6. However, in gender-stratified analyses, associations between PSQI subjective sleep quality and circulating IL-6 were non-significant in men (β = −0.03, SE = 0.02, p = 0.15) and women (β = 0.08, SE = 0.05, p = 0.11).

3.4. Role of sleep disturbances

Because of the consistent gender-specific associations between PSQI subjective sleep quality and 5-year changes in IL-6, CRP, and fibrinogen, we investigated whether endorsement of sleep disturbances, including difficulty falling asleep, frequent awakenings, and waking up too early, were associated with 5-year changes in these biomarkers. Similar to prior analyses, there were no associations between type of sleep disturbance and 5-year changes in biomarker levels in the sample as a whole (data not shown); however, several significant gender by sleep disturbance interactions emerged. In this regard, gender moderated the association between endorsement of “trouble falling asleep” and 5-year increases in IL-6 (interaction IL-6: b = −0.37, SE = 0.13, p = 0.003) as well as associations between an endorsed tendency to “wake up far too early” and 5-year increases in all three biomarkers (interaction IL-6: b = −0.33, SE = 0.12, p = 0.007; CRP: b = −0.48, SE = 0.23, p = 0.04; fibrinogen: b = −31.86, SE = 16.08, p = 0.05).

In gender-stratified analyses, there were no associations between sleep disturbance measures and 5-year changes in biomarkers in men (p's > 0.05). In women, endorsement of “trouble falling asleep” was a significant predictor of 5-year increases in circulating IL-6, independent of age, ethnicity, education, BMI, and regular snoring (b = 0.24, SE = 0.11, p = 0.03). However, this did not remain statistically significant after adjustment for lifestyle/psychosocial covariates (b = −0.20, SE = 0.12, p = 0.11). Women who endorsed at baseline a tendency to “wake up far too early” showed significant 5-year elevations in IL-6 (b = 0.31, SE = 0.11, p = 0.007) and fibrinogen (b = 32.35, SE = 15.52, p = 0.04), but not CRP (b = 0.31, SE = 0.19, p = 0.11). After adjusting for additional lifestyle/psychosocial covariates, medical comorbidities, medication use, and cardiac function, a tendency to “wake up far too early” remained a significant predictor of 5-year increases in IL-6 (b = 0.31, SE = 0.13, p = 0.01) but not fibrinogen (b = 30.98, SE = 17.13, p = 0.07). An endorsement of frequent awakenings (i.e., “wake up several times during the night”) was unrelated to 5-year changes in any of the biomarkers and was not moderated by gender.

4. Discussion

The present study examined cross-sectional and prospective associations of subjective sleep quality with biomarkers of inflammation and coagulation in a sample of men and women with established coronary heart disease. Contrary to our hypotheses, in this sample of outpatients we found no evidence that subjective sleep quality, as indexed by a single item of self-reported sleep quality from the Pittsburgh Sleep Quality Index (PSQI), was associated with cross-sectional or 5-year changes in levels of IL-6, CRP, and fibrinogen. However, in gender-specific analyses, women reporting poorer PSQI subjective sleep quality showed marked 5-year increases in all three biomarkers; no such association was seen in men. These associations withstood adjustment for a number of covariates, including sociodemographic and lifestyle/psychosocial characteristics, medical comorbidities, medication use,
and cardiac function. In addition, women who endorsed sleep disturbances at baseline, particularly an endorsed tendency to “wake up far too early”, predicted 5-year increases in IL-6 and to some extent fibrinogen, raising the possibility that specific aspects of sleep disruption may contribute to variation in biomarkers implicated in CHD progression. These results add to growing evidence that increased inflammation may contribute to the negative cardiovascular consequences often associated with poor sleep, including poor sleep quality.

The present findings contribute to a growing literature on gender differences in the link between sleep and inflammation. Indeed, Suarez (2008) demonstrated that higher PSQI sleep quality scores predicted higher levels of circulating IL-6 and CRP in a sample of premenopausal women, but not in men (Suarez, 2008). In the same study, higher levels of IL-6, CRP, and fibrinogen were observed in women who reported more frequent sleep disturbances, characterized primarily by difficulties falling asleep, as compared to men. The current study extends these findings by providing the first prospective evidence that poor subjective sleep quality is associated with inflammatory trajectories in women, which may help explain the stronger longitudinal links between sleep and incidence of hypertension and cardiovascular events observed in women as compared to men (Cappuccio et al., 2007; Newman et al., 2000).

The fact that sleep quality predicted 5-year changes in levels of biomarkers in women but was unrelated to these biomarkers at baseline and follow-up in cross-sectional analyses is difficult to reconcile, particularly given prior cross-sectional studies that support such gender differences (Miller et al., 2009; Suarez, 2008). One attribute that sets the current study apart from prior work, however, is that all participants had established CHD, which is a disease process marked by inflammatory activity. To the extent that CHD progressed in these participants from baseline to 5-year follow-up, it is possible that sleep quality would uniquely account for variation in rate of change in disease progression, as marked by elevations in markers inflammation and coagulation, but not when investigated cross-sectionally. Additional research utilizing other intermediate markers of CHD progression, such as intima-media thickness, is needed to test this possibility. If supported, this adds to the importance of assessing and treating sleep disturbance in vulnerable high-risk populations, including those with frank cardiovascular disease. Another explanation for why we observed longitudinal effects but not cross-sectional associations resides in the fact that while the presence of CHD is a stable attribute across this sample, it is otherwise heterogeneous. As such, sleep is only but one factor that can contribute to variability in inflammation. A constellation of other factors, including maladaptive dietary behaviors such as excess consumption of high sugar/high fat foods, and complex biological processes, including endothelial dysfunction and oxidative stress can contribute to heterogeneity in inflammatory activity. The strength of this longitudinal design, however, is the ability to isolate the effect of sleep on within-in subject changes in inflammation obviating the between-subject differences inherent in this population.

The physiologic mechanisms that underlie the gender differences observed in this study remain to be elucidated. In this regard, there is substantial evidence supporting the autonomic nervous system (ANS) in modulating inflammation (Nance and Sanders, 2007). For example, experimental increases in catecholamines upregulate NF-kB signaling pathways responsible for pro-inflammatory cytokine production (Bierhaus et al., 2003). Moreover, cross-sectional evidence shows heart rate variability, an index of the parasympathetic division of the ANS, is inversely associated with systemic levels of inflammation (Sloan et al., 2007). Sleep studies support increased sympathetic activation and parasympathetic withdrawal in those experiencing disrupted sleep, including insomniacs (Irwin et al., 2003) and patients with chronic disease (Palesh et al., 2008). Furthermore, laboratory evidence suggests that women show greater monocyte expression of IL-6 during undisturbed sleep than men, a difference that is moderated by sex differences in tonic sympathovagal activity (O’Connor et al., 2007). Differences in levels of reproductive hormones may also aid in explaining these gender disparities. Plasma concentrations of estradiol are lower in postmenopausal women (<15 pg/ml) than pre-menopausal women (50–250 pg/ml) and men (50 pg/ml) (Walsh and Shiff, 2001). Estradiol acts to inhibit inflammatory gene expression and cellular production of pro-inflammatory cytokines (Deshpande et al., 1997; Ray et al., 1997).

The women in this study were largely post-menopausal, and thus it is possible that lower circulating levels of reproductive hormones facilitated the increased levels of inflammatory activity associated with poor sleep. Of note, a small fraction of women reported use of hormone replacement therapy or oral contraceptives (OC) (n = 4); however, adjusting for use in our analyses had little influence on the results.

The lack of an association between subjective sleep quality and inflammation in men raises the possibility that testosterone may represent another important biological pathway. Indeed, higher levels of testosterone have been associated with lower levels of systemic inflammation, including IL-6 and CRP (Jones and Saad, 2009; Kapoor et al., 2007) and experimental studies demonstrate that testosterone replacement downregulates proinflammatory mediators in peripheral circulation (Malkin et al., 2004). Consequently, it is possible that testosterone, which is at higher levels in men, served to buffer the effects of poor subjective sleep quality on 5-year changes in inflammation. Future studies are needed to investigate the influence reproductive hormones, such as testosterone and estradiol, play in moderating the effects of sleep quality on systemic levels of inflammation and coagulation.

The strengths of this study include the large sample of patients with stable CHD, the prospective assessment of inflammation and coagulation, and the comprehensive measurement of potential confounding variables. However, several limitations must be considered in interpreting the results. First, the sample was restricted to older adults with CHD, limiting the generalizability of these results. In addition, sleep quality and sleep disturbance were assessed using single-item self-report measures. While there is evidence to suggest that a single-item measuring subjective sleep quality may be sufficient (Bush et al., 2012; Carpenter and Andrykowski, 1998), a more comprehensive characterization of sleep and sleep disturbance, including uses of objective sleep measures, such as actigraphy or in-home polysomnography, is needed in future studies. Another limitation is that this study was not explicitly designed to test gender differences. While our analyses supported several gender by sleep interactions, men comprised more than 80% of the sample. As such, future studies are needed using stratified samples to better clarify gender differences; that said, the findings in women may actually underestimate the true effect given the limited sample size. Finally, though we adjusted for history of regular snoring and BMI, obstructive sleep apnea (OSA), a well-known contributor to cardiovascular risk (Gottlieb et al., 2010; Shahar et al., 2001) and elevated inflammation (Shamsuzzaman et al., 2002), was not formally assessed in this study.

In conclusion, these findings provide the first prospective evidence for subjective sleep quality predicting 5-year increases in markers of inflammation and coagulation among women with established CHD. While this work requires replication, these results provide important evidence that inflammation may serve as a key biological pathway through which disturbed sleep contributes to CHD progression in women.
Role of funding source

This research was supported in part by NIH/NHLBI Grant K08 HL112961 and a Robert Wood Johnson Foundation Health and Society Scholars fellowship to Dr. Prather. The Heart and Soul Study was funded by the Department of Veterans Affairs, Washington DC, the National Heart, Lung and Blood Institute (R01 HL079235), Bethesda, MD, the American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY, the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, NJ, and the Ischemia Research and Education Foundation, South San Francisco, CA.

Contributors

Dr. Whooley designed the overall study and coordinated all data collection. Dr. Cohen assisted in coordinating data collection. Dr. Prather wrote the first draft of the manuscript and carried out all statistical analyses. Drs. Whooley, Cohen, Epel, and Neylan aided in editing the initial draft. All authors contributed to and approved the final manuscript.

Conflict of interest

The authors have indicated no financial conflicts of interest with respect to this manuscript.

Acknowledgments

The authors would like to thank The Heart and Soul Study team for supporting this manuscript, particularly Mathilda Regan and Bee Ya Na.

References

Hall MH, Maddon MF, Jennum PJ, Buysse DJ, Flory JD, Manuck SB. Self-reported sleep duration is associated with the metabolic syndrome in midlife adults. Sleep 2008;31:635–43.
Okun ML, Coussoules-Read M, Hall M. Disturbed sleep is associated with increased C-reactive protein in young women. Brain, Behavior, and Immunity 2009;23:351–6.


Taheri S, Austin D, Lin L, Nieto FJ, Young T, Mignot E. Correlates of serum C-reactive protein (CRP)—no association with sleep duration or sleep disordered breathing. Sleep 2007;30:991–6.


